Depression Drugs Market: Popularity of Tech-based Mental Health Apps also Contributing to Low Sales

Rockville, USA, 2019-Apr-01 — /EPR Network/ —  Fact.MR analysis the global depression drugs market for the forecast period 2018 – 2026. The exhaustive study is aimed at recognizing lucrative opportunities available in the global depression drugs market. The study offers updates and insights into various categories of the depression drugs market. The comprehensive study begins with a detailed overview of the depression drugs market, which assesses the market performance in terms of revenue, key trends, restraints, and drivers prevailing in the global depression drugs market.

Request Free Sample Report Here:

https://www.factmr.com/connectus/sample?flag=S&rep_id=3215

According to the World Health Organization (WHO), depression has become one of the common illnesses, affecting over 300 million people across the world. In the United States, approximately 10.3 million adults had experienced at least one major depressive episode that resulted in severe impairment, according to the National Institute of Mental Health (NIMH). High prevalence of such depressive episode was observed among people aged 18-25 (10.9%), female adults (8.5%), and male adults (4.8%). According to the Fact.MR study, although depression continues to be a major health issue, medical community and patients are encouraging a non-drug approach to reduce side effects and dependency. Healthcare providers and patients are focusing on cognitive behavior therapy (CBT) and mindfulness-based approaches to foster a long-term management of depression and other mental health issues.

Browse Full report on  Market with TOC:

https://www.factmr.com/report/3215/depression-drugs-market

Depression Drugs Market: Segment-wise Insights

  • On the basis of drug class, the global depression drugs market has been segmented into SSRIs, atypical antipsychotics, SNRIs, CNS stimulants, and others. Of these, atypical antipsychotics is expected to contribute the largest share in the market.
  • Major depressive disorder has been envisaged to account for the most substantial share in the depression drugs market based on disease type. Other sub-segments include SSRI induced, schizophrenia, and bipolar I disorder.
  • While depression drugs are sold across retail, hospital, and online pharmacies, the retail segment registered the largest share in 2017, and the trend is expected to continue during the 2018-2026 period.

 

Fact.MR offers accurate data depending on supply side, demand side, and dynamics of the global depression drugs market. This comprehensive study encompasses market forecast in terms of revenue (US$ Mn). This in-depth study also offers stats on Year-on-Year (Y-o-Y) growth of the depression drugs market. Key information about the depression drugs market share is drawn through regional pricing trends. Market size and forecast for each section have been incorporated in terms of the global and regional depression drugs markets. The market has been weighed based on the robust demand determinants. The values used for calculating the market size are obtained through primary researches carried out by setting up interviews with a number of manufacturers, distributors, and suppliers of the depression drugs market.

Global Depression Drugs Market: Competitive Landscape

Some key players operating in the manufacturing of depression drugs are Otsuka Pharmaceutical Co., Ltd., Johnson & Johnson, Sebela Pharmaceutical Inc., GlaxoSmithKline plc, AstraZeneca plc, Eli Lilly and Company, Allergan USA, Inc., Takeda Pharmaceutical Company Ltd, Novartis AG, Pfizer, Inc., Alkermes Plc, H. Lundbeck, Bristol Myers Squibb Co., and Teva Pharmaceutical Industries Ltd.

Have Any Query?? Ask Our Industry Expert:

https://www.factmr.com/connectus/sample?flag=AE&rep_id=3215

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Fact.MR

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

sales@factmr.com

www.factmr.com

Read Full PR Here:

https://www.factmr.com/media-release/935/depression-drugs-market

Matched content

Editor’s pick

Express Press Release Distribution